Obesity Pipeline Summary

DelveInsight’s, “Obesity - Pipeline Insight, 2026” report provides comprehensive insights about 200+ companies and 200+ pipeline drugs in Obesity pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Obesity: Understanding

Obesity: Overview

Obesity is a chronic, relapsing, adiposity-based disease characterized by excessive or abnormal body fat that can impair physical health and increase morbidity and mortality. Traditionally, obesity in adults is defined using BMI ?30 kg/m², although newer frameworks emphasize that BMI alone does not capture fat distribution or obesity-related organ dysfunction. Central adiposity, excess body fat and associated complications are increasingly incorporated into diagnosis.

Common signs and symptoms include excess body weight, increased waist circumference, breathlessness, fatigue, reduced physical mobility, joint discomfort and sleep disturbances. Obesity is multifactorial and results from interactions among genetic susceptibility, energy imbalance, dietary patterns, physical inactivity, environmental factors, medications, socioeconomic conditions and neuroendocrine regulation.

Pathophysiologically, obesity develops when energy intake chronically exceeds energy expenditure, resulting in adipocyte enlargement and expansion of adipose tissue. Excess adiposity can promote chronic low-grade inflammation, insulin resistance, altered adipokine signaling and metabolic dysfunction, contributing to type 2 diabetes, cardiovascular disease, fatty liver disease, sleep apnoea and musculoskeletal disorders.

Diagnosis of obesity begins with assessment of body mass index (BMI), with a BMI ?30 kg/m² generally classified as obesity in adults; however, BMI alone does not accurately reflect body-fat distribution or health risk. Waist circumference is therefore often measured to identify central or visceral adiposity, while body-composition techniques such as DXA or bioelectrical impedance may be used when additional assessment is required.

Clinical evaluation includes medical and family history, weight trajectory, diet, physical activity, medications, sleep, and potential secondary causes such as endocrine disorders. Clinicians also assess obesity-related complications through blood pressure measurement and laboratory tests such as glucose/HbA1c, lipid profile and liver-function tests. Increasingly, diagnosis emphasizes the amount and distribution of excess adiposity together with its impact on organ function and overall health, rather than relying on BMI alone.

Treatment is individualized and aims not only to reduce weight but also to improve obesity-related complications and overall health. Lifestyle management, including nutritional intervention, physical activity and behavioral support, remains foundational; however, long-term physiological adaptations can make sustained weight loss difficult. Pharmacotherapy may be added when clinically appropriate, with current options including GLP-1 receptor agonists and GLP-1/GIP-based therapies such as semaglutide and tirzepatide, alongside other approved anti-obesity medicines. For selected patients with severe or complicated obesity, metabolic/bariatric surgery provides the most durable weight-loss option.

"Obesity- Pipeline Insight, 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Obesity pipeline landscape is provided which includes the disease overview and Obesity treatment guidelines. The assessment part of the report embraces, in depth Obesity commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Obesity collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Obesity R&D. The therapies under development are focused on novel approaches to treat/improve Obesity.

Obesity Emerging Drugs Chapters

This segment of the Obesity report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Obesity Emerging Drugs

• Retatrutide: Eli Lilly and Company

Retatrutide is an investigational once-weekly injectable triple agonist developed by Eli Lilly that simultaneously activates the GIP, GLP-1, and glucagon receptors for the treatment of obesity. It is designed to promote weight loss through complementary effects on appetite, glucose metabolism, and energy expenditure. In Phase III obesity trials, retatrutide demonstrated significant reductions in body weight and HbA1c, with results supporting its continued development as a potential treatment for obesity and related metabolic conditions. Retatrutide remains investigational and is not yet approved for obesity. Currently, the drug is in Phase III of its development for the treatment of Obesity.

• Enicepatide: F. Hoffmann-La Roche

Enicepatide (CT-388) is an investigational once-weekly subcutaneous dual GLP-1/GIP receptor agonist being developed by Roche for chronic weight management in people with obesity or overweight. It is designed to activate both GLP-1 and GIP receptors while minimising ?-arrestin recruitment, potentially enabling sustained receptor activity. Enicepatide has demonstrated significant weight-loss effects in Phase II studies, including up to 22.7% mean body-weight reduction at 48 weeks at the highest dose. It is currently being evaluated in Phase III in adults with obesity or overweight, with or without type 2 diabetes.

• KDS2010: NeuroBiogen / Scelix Bio

KDS2010 is an investigational reversible monoamine oxidase-B (MAO-B) inhibitor being developed by NeuroBiogen for the treatment of obesity. It is designed as an oral, once-daily therapy, with the potential to address obesity through a mechanism distinct from incretin-based treatments. KDS2010 is being evaluated for its effects on body weight, body composition, metabolic parameters, and MAO-B activity. The ongoing Phase IIa study is assessing 120 mg, 180 mg, and 240 mg doses in adults with overweight or obesity. Currently, the drug is being evaluated in the Phase II stage of its development for the treatment of Obesity.

• WVE-007: Wave Life Sciences

WVE-007 is an investigational INHBE-targeting GalNAc-siRNA therapy developed by Wave Life Sciences for the treatment of obesity and cardiometabolic diseases. It is designed to silence INHBE mRNA, thereby reducing Activin E signaling and promoting fat loss while preserving lean muscle mass. WVE-007 is administered by subcutaneous injection and has demonstrated reductions in visceral and total body fat in early clinical studies. The ongoing Phase I/IIa INLIGHT trial is evaluating its safety, pharmacokinetics, pharmacodynamics, and effects on body composition and weight in adults with overweight or obesity. Currently, the drug is being evaluated in the Phase I/II stage of its development for the treatment of Obesity

• ASC36: Ascletis Pharma Inc.

ASC36 is an investigational next-generation amylin receptor peptide agonist being developed by Ascletis Pharma for the treatment of obesity. It is designed as a long-acting injectable therapy, with potential dosing once monthly to once quarterly. By activating amylin receptors, ASC36 is intended to regulate appetite and promote weight loss through effects on satiety and energy balance. In August 2026, Ascletis initiated a Phase I study in the US following FDA clearance of its IND application.

• NBIP-'1968: Neurocrine Biosciences

NBIP-'1968 is an investigational long-acting GLP-1/GIP/glucagon receptor triple agonist being developed by Neurocrine Biosciences for the treatment of obesity. It is designed for once-weekly subcutaneous administration, simultaneously targeting three complementary metabolic pathways involved in appetite regulation, energy balance, and glycemic control. The candidate incorporates balanced glucagon receptor activity with the aim of maximizing metabolic benefits while supporting tolerability. In August 2026, Neurocrine initiated a Phase I first-in-human study to evaluate its safety and tolerability in adults with varying BMI categories. Currently, the drug is in Phase I stage of its development for the treatment of Obesity.

Further product details are provided in the report……..

Obesity: Therapeutic Assessment

This segment of the report provides insights about the different Obesity drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Obesity

There are approx. 200+ key companies which are developing the therapies Obesity. The companies which have their Obesity drug candidates in the most advanced stage, i.e. Phase III include Eli Lilly and Company, and others.

• Phases

DelveInsight’s report covers around 200+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

• Route of Administration

Obesity pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

• Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Obesity: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Obesity therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Obesity drugs.

Obesity Report Insights

• Obesity Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Obesity Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Obesity drugs?
• How many Obesity drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Obesity?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Obesity therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Obesity and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Eli Lilly and Company
• Roche
• NeuroBiogen
• Ascletis Pharma Inc.
• Wave Life Sciences
• Neurocrine Bioscinces
• Pfizer
• Suzhou Siran Biotechnology
• GSK
• Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
• Jiangsu Hansoh Pharmaceutical Co., Ltd.
• BrightGene Bio-medical technology
• Huons Co., Ltd.
• S1 Biopharma, Inc.
• AbbVie
• Sirius Therapeutics Co., Ltd.
• Suzhou Sanegene Bio Inc.
• Boehringer Ingelheim/Gubra
• HongKong Curegene Innovation Co., Limited
• CSPC ZhongQi Pharmaceutical Technology Co., Ltd./Astrazeneca
• Merck Sharp & Dohme LLC
• Hanmi Pharmaceutical Company Limited
• Alveus Therapeutics, Inc.
• Syntis Bio
• Alnylam Pharmaceuticals
• Viking Therapeutics

Key Products

• Retatrutide
• Enicepatide
• KDS2010
• WVE-007
• ASC36
• NBIP-'1968
• Berobenatide
• SA030
• HDM1005
• HS-20136-2
• BGM0504
• HUC2-676
• S1B-509
• ABBV 295
• SRSD384
• SGB-7342
• BI 3034701
• CG-0416
• SYH2082
• MK-4082
• HM17321
• ALV-100
• SYNT-101
• ALN-6222
• VK2735